Applies to: Visual Defect/DisturbanceOptic neuropathy and/or neuritis has occurred during administration of amiodarone and has resulted in visual impairment such as changes in visual acuity, decrease in peripheral vision, and blindness. More frequently, asymptomatic abnormal diffusion capacity has been observed. 2017 Sep;28(3):307-316. doi: 10.1007/s00399-017-0516-0.HeartRhythm Case Rep. 2016 Jan 20;2(2):178-182. doi: 10.1016/j.hrcr.2016.01.006. In some cases, these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsade de pointes. Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias. Flecainide (Tambocor) ... Amiodarone (Cordarone) 150 mg IV over 10 minutes, then 30 to 60 mg IV per hour; 200 to 400 mg orally every day as a maintenance dose after loading. Switching Antiarrhythmics Drug Half-Life Minimum Wash-out Amiodarone 53+ days Often not possible Dofetilide 10 hours 36 hours Dronedarone 13-19 hours 48 hours Flecainide 12-24 hours 36 hours Propafenone Extensive metabolizers: 2-10 hrs Poor metabolizers: 10-32 hrs 72 hours Sotalol 8-12 hours 36 hours 28. Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients. Applies to: Hyperthyroidism, HypothyroidismAmiodarone inhibits peripheral conversion of thyroxine (T4) to triiodothyronine (T3) and also contributes inorganic iodine that can result in altered thyroid function tests, hypothyroidism, or hyperthyroidism. Hypokalemia and hypomagnesemia can reduce the effectiveness of antiarrhythmic agents. Applies to: Hypokalemia, Hyperkalemia, Magnesium ImbalanceElectrolyte imbalance can alter the therapeutic effectiveness of antiarrhythmic agents. 43 to 68. Accordingly, the mean dose of flecainide required to maintain similar plasma levels of the drug was one-third lower during combined treatment than during therapy with flecainide alone. Therapy with amiodarone should be administered cautiously in patients with visual defects. Flecainide (Tambocor): Flecainide is a potent sodium channel blocker that may be used in atrial fibrillation patients without structural heart disease. Ann Intern Med 114 (1991): 189-94 Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias. There is no precise protocol for switching from IV to oral treatment but the following method for calculating the oral dose required may be used. BACKGROUND The effectiveness of amiodarone and propafenone in the treatment of patients with chronic atrial fibrillation has not been adequately studied. Applies to: Heart Block, Cardiogenic ShockThe use of amiodarone is contraindicated for use in patients with cardiogenic shock, severe sinus node dysfunction causing marked sinus bradycardia, second- or third-degree AV block, or symptomatic bradycardia in the absence of a functioning pacemaker.Major Potential Hazard, Low plausibility.
1984 Mar;7(2):272-5. doi: 10.1111/j.1540-8159.1984.tb04897.x.Herzschrittmacherther Elektrophysiol. Modification of thyroid therapy may be necessary.Moderate Potential Hazard, High plausibility. 1989 Aug;17(2):130-40. doi: 10.2165/00003088-198917020-00005. COVID-19 is an emerging, rapidly evolving situation. Of these, we prefer flecainide or propafenone … Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations View in … Thus, the risks and benefits of amiodarone therapy should be weighed carefully. 1985 Mar;109(3 Pt 1):523-8. doi: 10.1016/0002-8703(85)90557-5.Singh BN, Nademanee K, Josephson MA, Ikeda N, Venkatesh N, Kannan R.Ann N Y Acad Sci.
Patients who develop hypersensitivity pneumonitis should be withdrawn permanently from amiodarone therapy and treated with steroids.
Applies to: Liver DiseaseThere have been rare reports of fatal hepatocellular necrosis after treatment with amiodarone.
1984 Mar;7(2):272-5. doi: 10.1111/j.1540-8159.1984.tb04897.x.Herzschrittmacherther Elektrophysiol. Modification of thyroid therapy may be necessary.Moderate Potential Hazard, High plausibility. 1989 Aug;17(2):130-40. doi: 10.2165/00003088-198917020-00005. COVID-19 is an emerging, rapidly evolving situation. Of these, we prefer flecainide or propafenone … Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations View in … Thus, the risks and benefits of amiodarone therapy should be weighed carefully. 1985 Mar;109(3 Pt 1):523-8. doi: 10.1016/0002-8703(85)90557-5.Singh BN, Nademanee K, Josephson MA, Ikeda N, Venkatesh N, Kannan R.Ann N Y Acad Sci.
Patients who develop hypersensitivity pneumonitis should be withdrawn permanently from amiodarone therapy and treated with steroids.
Applies to: Liver DiseaseThere have been rare reports of fatal hepatocellular necrosis after treatment with amiodarone.
1984 Mar;7(2):272-5. doi: 10.1111/j.1540-8159.1984.tb04897.x.Herzschrittmacherther Elektrophysiol. Modification of thyroid therapy may be necessary.Moderate Potential Hazard, High plausibility. 1989 Aug;17(2):130-40. doi: 10.2165/00003088-198917020-00005. COVID-19 is an emerging, rapidly evolving situation. Of these, we prefer flecainide or propafenone … Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations View in … Thus, the risks and benefits of amiodarone therapy should be weighed carefully. 1985 Mar;109(3 Pt 1):523-8. doi: 10.1016/0002-8703(85)90557-5.Singh BN, Nademanee K, Josephson MA, Ikeda N, Venkatesh N, Kannan R.Ann N Y Acad Sci.
Patients who develop hypersensitivity pneumonitis should be withdrawn permanently from amiodarone therapy and treated with steroids.
Applies to: Liver DiseaseThere have been rare reports of fatal hepatocellular necrosis after treatment with amiodarone.
Figge J, Dluhy RG "Amiodarone-induced elevation of thyroid stimulating hormone in patients receiving levothyroxine for primary hypothyroidism." eCollection 2016 Mar.Pharm Res. Clipboard, Search History, and several other advanced features are temporarily unavailable. Dubner SJ, Elencwajg BD, Palma S, Mendelzon R, Ramos A, Bertolasi CA.Am Heart J. doi: 10.1016/s0735-1097(86)80234-0. Patients with hepatic impairment should be monitored for evidence of progressive hepatic injury. Applies to: Visual Defect/DisturbanceOptic neuropathy and/or neuritis has occurred during administration of amiodarone and has resulted in visual impairment such as changes in visual acuity, decrease in peripheral vision, and blindness. More frequently, asymptomatic abnormal diffusion capacity has been observed. 2017 Sep;28(3):307-316. doi: 10.1007/s00399-017-0516-0.HeartRhythm Case Rep. 2016 Jan 20;2(2):178-182. doi: 10.1016/j.hrcr.2016.01.006. In some cases, these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsade de pointes. Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias. Flecainide (Tambocor) ... Amiodarone (Cordarone) 150 mg IV over 10 minutes, then 30 to 60 mg IV per hour; 200 to 400 mg orally every day as a maintenance dose after loading. Switching Antiarrhythmics Drug Half-Life Minimum Wash-out Amiodarone 53+ days Often not possible Dofetilide 10 hours 36 hours Dronedarone 13-19 hours 48 hours Flecainide 12-24 hours 36 hours Propafenone Extensive metabolizers: 2-10 hrs Poor metabolizers: 10-32 hrs 72 hours Sotalol 8-12 hours 36 hours 28. Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients. Applies to: Hyperthyroidism, HypothyroidismAmiodarone inhibits peripheral conversion of thyroxine (T4) to triiodothyronine (T3) and also contributes inorganic iodine that can result in altered thyroid function tests, hypothyroidism, or hyperthyroidism. Hypokalemia and hypomagnesemia can reduce the effectiveness of antiarrhythmic agents. Applies to: Hypokalemia, Hyperkalemia, Magnesium ImbalanceElectrolyte imbalance can alter the therapeutic effectiveness of antiarrhythmic agents. 43 to 68. Accordingly, the mean dose of flecainide required to maintain similar plasma levels of the drug was one-third lower during combined treatment than during therapy with flecainide alone. Therapy with amiodarone should be administered cautiously in patients with visual defects. Flecainide (Tambocor): Flecainide is a potent sodium channel blocker that may be used in atrial fibrillation patients without structural heart disease. Ann Intern Med 114 (1991): 189-94 Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias. There is no precise protocol for switching from IV to oral treatment but the following method for calculating the oral dose required may be used. BACKGROUND The effectiveness of amiodarone and propafenone in the treatment of patients with chronic atrial fibrillation has not been adequately studied. Applies to: Heart Block, Cardiogenic ShockThe use of amiodarone is contraindicated for use in patients with cardiogenic shock, severe sinus node dysfunction causing marked sinus bradycardia, second- or third-degree AV block, or symptomatic bradycardia in the absence of a functioning pacemaker.Major Potential Hazard, Low plausibility.
1984 Mar;7(2):272-5. doi: 10.1111/j.1540-8159.1984.tb04897.x.Herzschrittmacherther Elektrophysiol. Modification of thyroid therapy may be necessary.Moderate Potential Hazard, High plausibility. 1989 Aug;17(2):130-40. doi: 10.2165/00003088-198917020-00005. COVID-19 is an emerging, rapidly evolving situation. Of these, we prefer flecainide or propafenone … Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations View in … Thus, the risks and benefits of amiodarone therapy should be weighed carefully. 1985 Mar;109(3 Pt 1):523-8. doi: 10.1016/0002-8703(85)90557-5.Singh BN, Nademanee K, Josephson MA, Ikeda N, Venkatesh N, Kannan R.Ann N Y Acad Sci.
Patients who develop hypersensitivity pneumonitis should be withdrawn permanently from amiodarone therapy and treated with steroids.
Applies to: Liver DiseaseThere have been rare reports of fatal hepatocellular necrosis after treatment with amiodarone.
Unable to load your collection due to an error This is only a rough method of calculation, and … Please enable it to take advantage of the complete set of features! Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.Major Potential Hazard, High plausibility. Flecainide, propafenone, ibutilide, dofetilide, procainamide, and, to a lesser degree, amiodarone have efficacy for pharmacologic conversion of AF. 1987 Jun;4(3):251-4. doi: 10.1023/a:1016468430618.Clin Pharmacokinet. OBJECTIVES The purpose of this study was to investigate the efficacy and safety of amiodarone and propafenone in the conversion of chronic atrial fibrillation in a prospective, randomized, placebo-controlled study. Unable to load your delegates due to an error Treatment or suppression of euthyroid Elsevier Science
Got something to say?